This study focuses on treating advanced pancreatic cancer that cannot be removed by surgery and doesn't have a KRAS mutation. KRAS refers to a gene that, when mutated, can cause cancer. Researchers are testing if adding a drug called panitumumab to standard chemotherapy (a treatment using powerful drugs to kill cancer cells) works better than chemotherapy alone. Panitumumab is a special protein that targets cancer cells to stop them from growing and spreading.

• The study lasts up to 3 years with regular checkups and tests like CT scans.
• Participants will be randomly placed in two groups, with one receiving panitumumab and chemotherapy, and the other just chemotherapy.
• Patients will get treatment every 28 days unless the cancer worsens or there are bad side effects.

Consider joining if you have pancreatic cancer without KRAS mutations and have not received certain treatments before. This study aims to improve survival rates and understand side effects. Participants should be over 18, not pregnant, and have specific blood test results. Regular follow-ups and tests are crucial for this study.